Zai Lab Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZLAB Nasdaq 2836 www.zailaboratory.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zai Lab Limited

Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Apr 30th, 2026 8:42 am
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - Apr 29th, 2026 8:37 am
Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target Reset - Apr 28th, 2026 5:06 am
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call - Apr 26th, 2026 12:02 am
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading - Apr 23rd, 2026 8:44 am
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 - Apr 22nd, 2026 5:30 am
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Apr 19th, 2026 9:43 am
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases - Apr 18th, 2026 7:00 am
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas - Apr 17th, 2026 1:01 pm
Asian Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading - Apr 15th, 2026 8:44 am
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - Apr 15th, 2026 6:00 am
Amgen And Zai Lab Trial Tests DLL3 Combo As Valuation Looks Undemanding - Apr 14th, 2026 11:03 am
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile - Apr 2nd, 2026 8:12 pm
Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading - Apr 1st, 2026 8:36 am
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - Apr 1st, 2026 5:30 am
JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 – Here’s Why - Mar 31st, 2026 9:06 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - Mar 27th, 2026 8:37 am
A Look At Zai Lab (ZLAB) Valuation After A Sharp Pullback And Fair Value Gap - Mar 25th, 2026 4:05 am
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) - Mar 17th, 2026 2:35 pm
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - Mar 13th, 2026 8:55 am